Investigation of the radioprotective efficacy of hesperidin against gamma-radiation induced cellular damage in cultured human peripheral blood lymphocytes.
The present study was aimed to evaluate the radioprotective efficacy of hesperidin (HN), a flavonone glycoside against gamma-radiation-induced cellular damage in cultured human peripheral blood lymphocytes. Different concentrations of HN (3.27, 6.55, 9.83, 13.10, 16.38 and 19.65 microM) were pre-incubated with lymphocytes for 30 min prior to gamma-irradiation [4 Gy] and the micronuclei (MN) scoring, dicentric aberration and comet assay were performed to fix the effective dose of HN against gamma-irradiation induced cellular damage. The results indicated that among all the concentrations, 16.38 microM concentration of HN showed optimum protection by effectively decreasing the MN frequencies, dicentric aberrations and comet attributes. Based on the above results, 16.38 microM concentration of HN was fixed as the effective dose to further investigate its radioprotective efficacy which was then carried out by pre-incubating lymphocytes with 16.38 microM concentration of HN, exposing the lymphocytes to different doses (1, 2, 3 and 4 Gy) of radiation and investigating radiation induced genetic damage (MN, dicentric aberration, comet assay, DNA fragmentation assay) and biochemical changes (changes in the level of enzymic and non-enzymic antioxidants, lipid peroxidation). The results indicated a dose dependent increase in both genetic damage and thiobarbituric acid reactive substances (TBARS), accompanied by a significant decrease in the antioxidant status compared to HN treated groups which modulated the toxic effects through its antioxidant potential. Thus the current study shows HN to be an effective radioprotector against gamma-radiation induced in-vitro cellular damage in lymphocytes.
Kalpana
K B
KB
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar-608002, Tamil Nadu, India.
Devipriya
N
N
Srinivasan
M
M
Menon
Venugopal P
VP
D048868:Adaptor Proteins, Signal Transducing; D002352:Carrier Proteins; D002469:Cell Separation; D002478:Cells, Cultured; D002869:Chromosome Aberrations / Q000528:radiation effects; D020552:Comet Assay; D004249:DNA Damage / Q000187:drug effects*; D053938:DNA Fragmentation / Q000187:drug effects* / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D016166:Free Radical Scavengers; D005720:Gamma Rays; D006569:Hesperidin / Q000494:pharmacology*; D006801:Humans; D007958:Leukocyte Count; D015227:Lipid Peroxidation; D008214:Lymphocytes / Q000187:drug effects* / Q000502:physiology / Q000528:radiation effects; D015162:Micronucleus Tests; D018384:Oxidative Stress / Q000187:drug effects*; D011829:Radiation Dosage; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D012097:Repressor Proteins
D048868:Adaptor Proteins, Signal Transducing; C101409:CCDC85B protein, human; D002352:Carrier Proteins; D016166:Free Radical Scavengers; D011837:Radiation-Protective Agents; D012097:Repressor Proteins; D006569:Hesperidin